Epithelial-Mesenchymal Transition (EMT) Protein Expression in a Cohort of Stage II Colorectal Cancer Patients With Characterized Tumor Budding and Mismatch Repair Protein Status

Introduction and aims The role of genetic factors in the etiology and prognosis of patients with sporadic colorectal cancer is controversial. We have therefore investigated the biological and clinicopathological influence of immunohistochemical MSH2 expression in colorectal cancer. Patients and methods A total of 49 consecutive patients with unselected colorectal cancer operated on in our unit were included in the study. All tumors were resected and tumor specimens were evaluated for MSH2 expression. Clinicopathological data and patient survival were correlated with MSH2 staining. Uni- and multivariate analyses were performed. The minimum follow-up period was five years. Results Curative resection was performed in 34 patients (64.9%), 14 of whom subsequently relapsed. At the end of the overall follow-up 25 (51%) patients had died, 21 of cancer-related causes. Twenty-eight patients (57.1%) were negative for MSH2 staining. Only vascular invasion was significantly correlated with MSH2 expression (lower median values; p=0.04). The overall median survival was 47.9 months (95% CI=27–86.6%). Multivariate analysis of variables in relation to survival showed that T stage (p=0.001), N stage (p<0.001) and MSH2 expression (p=0.01) were independent factors for survival. Conclusions Reduced MSH2 expression is frequent in unselected colorectal cancer patients. Only vascular invasion was correlated with MSH2 expression in this study. Survival was related to TN stage and MSH2 staining.

Download Full-text

Association of Tumor Morphology With Mismatch-repair Protein Status in Older Endometrial Cancer Patients

The American Journal of Surgical Pathology ◽

10.1097/pas.0000000000000177 ◽

2014 ◽

Vol 38 (6) ◽

pp. 793-800 ◽

Cited By ~ 43

Author(s):

Joseph T. Rabban ◽

Sarah M. Calkins ◽

Anthony N. Karnezis ◽

James P. Grenert ◽

Amie Blanco ◽

...

Keyword(s):

Endometrial Cancer ◽

Cancer Patients ◽

Mismatch Repair ◽

Tumor Morphology ◽

Protein Status ◽

Repair Protein ◽

Mismatch Repair Protein

Download Full-text

Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients

International Journal of Molecular Sciences ◽

10.3390/ijms22095019 ◽

2021 ◽

Vol 22 (9) ◽

pp. 5019

Author(s):

Helena Oliveres ◽

David Pesántez ◽

Joan Maurel

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Tyrosine Kinases ◽

Epithelial To Mesenchymal Transition ◽

Acquired Resistance ◽

Post Translational Modification ◽

Mesenchymal Transition ◽

Igf1r Signaling ◽

Colorectal Cancer Patients

Insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine kinase that regulates cell growth and proliferation. Upregulation of the IGF1R pathway constitutes a common paradigm shared with other receptor tyrosine kinases such as EGFR, HER2, and MET in different cancer types, including colon cancer. The main IGF1R signaling pathways are PI3K-AKT and MAPK-MEK. However, different processes, such as post-translational modification (SUMOylation), epithelial-to-mesenchymal transition (EMT), and microenvironment complexity, can also contribute to intrinsic and acquired resistance. Here, we discuss new strategies for adequate drug development in metastatic colorectal cancer patients.

Download Full-text